Search
Elinzanetant
go.drugbank.com/drugs/DB18968ApprovedInvestigationalElinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. By b...
Categories: Cytochrome P-450 CYP3A Inhibitors, P-glycoprotein substratesFlorquinitau (18F)
go.drugbank.com/drugs/DB19215ApprovedFlorquinitau F 18 is a radioactive diagnostic drug used as a fluorine-18–labeled positron emission tomography (PET) tracer. It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that ar...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesHydrastinine
go.drugbank.com/drugs/DB19359ExperimentalCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalSiponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesOmadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over t...
Categories: P-glycoprotein substratesIbrexafungerp
go.drugbank.com/drugs/DB12471ApprovedIbrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. It was developed out of...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigationalMirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound D...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesOzanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalOzanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approve...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigationalGivinostat is a small molecule histone deacetylase (HDAC) inhibitor. It has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lympho...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersDihydralazine
go.drugbank.com/drugs/DB12945ApprovedWithdrawnDihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors